Results 21 to 30 of about 45,216 (237)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma

Frontiers in Oncology, 2021
Sorafenib a multi-target tyrosine kinase inhibitor, is the first-line drug for treating advanced hepatocellular carcinoma (HCC). Mechanistically, it suppresses tumor angiogenesis, cell proliferation and promotes apoptosis.
Zhi Zeng, Zhi Zeng, Qiliang Lu, Qiliang Lu, Yang Liu, Yang Liu, Junjun Zhao, Junjun Zhao, Qian Zhang, Linjun Hu, Linjun Hu, Zhan Shi, Yifeng Tu, Zunqiang Xiao, Qiuran Xu, Dongsheng Huang   +15 more
doaj   +1 more source

ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer. [PDF]

Transl Oncol
Lin YH, Chen CY, Chi HC, Wu MH, Lai MW, Yeh CT.   +5 more
europepmc   +2 more sources

Artesunate Regulates Neurite Outgrowth Inhibitor Protein B Receptor to Overcome Resistance to Sorafenib in Hepatocellular Carcinoma Cells

Frontiers in Pharmacology, 2021
The multireceptor tyrosine kinase inhibitor sorafenib is a Food and Drug Administration-approved first-line drug for the treatment of advanced liver cancer that can reportedly extend overall survival in patients with advanced hepatocellular carcinoma ...
Wubin He, Xiaoxu Huang, Bradford K. Berges, Yue Wang, Ni An, Rongjian Su, Yanyan Lu   +6 more
doaj   +1 more source

Anterior gradient 2 induces resistance to sorafenib via endoplasmic reticulum stress regulation in hepatocellular carcinoma

Cancer Cell International, 2023
Background Hepatocellular carcinoma (HCC) accounts for almost 80% of all liver cancer cases and is the sixth most common cancer and the second most common cause of cancer-related death worldwide.
Hung-Wen Tsai, Yi-Li Chen, Chun-I Wang, Ching‑Chuan Hsieh, Yang-Hsiang Lin, Pei-Ming Chu, Yuh-Harn Wu, Yi-Ching Huang, Cheng-Yi Chen   +8 more
doaj   +1 more source

ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma

Neoplasia: An International Journal for Oncology Research, 2021
Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), and reducing sorafenib resistance is an important issue to be resolved for the clinical treatment of HCC.
Wenbin Huang, Kunling Chen, Yishi Lu, Donghui Zhang, Yuan Cheng, Liuran Li, Weimei Huang, Guolin He, Hangyu Liao, Lei Cai, Yujun Tang, Liang Zhao, Mingxin Pan   +12 more
doaj   +1 more source

SMYD3 induces sorafenib resistance by activating SMAD2/3-mediated epithelial-mesenchymal transition in hepatocellular carcinoma

iScience, 2023
Summary: Drug resistance prominently hampers the effects of systemic therapy of sorafenib to hepatocellular carcinoma (HCC). Epigenetics have critical regulatory roles in drug resistance.
Shanshan Wang, Xin You, Xiaoshu Liu, Fengwei Zhang, Hongjuan Zhou, Xuechai Shang, Long Cai   +6 more
doaj   +1 more source

A comprehensive review of the relationship between autophagy and sorafenib-resistance in hepatocellular carcinoma: ferroptosis is noteworthy

Frontiers in Cell and Developmental Biology, 2023
Patients with hepatocellular carcinoma (HCC) bear a heavy burden of disease and economic burden but have fewer treatment options. Sorafenib, a multi-kinase inhibitor, is the only approved drug that can be used to limit the progression of inoperable or ...
Kangnan Zhang, Qinghui Zhang, Rongrong Jia, Shihao Xiang, Ling Xu   +4 more
doaj   +1 more source

Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement [PDF]

, 2015
Hepatocellular carcinoma (HCC) is the most common malignancy of the liver and the third cause of cancer death worldwide. Chronic hepatitis due to HBV and HCV infection are two major risk factors for HCC worldwide.
Cuestas, María Luján, Mathet, Veronica Lidia, Oubiña, Jose Raul   +2 more
core   +1 more source

Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma

Hepatology, EarlyView., 2022
Steatotic HCC can be diagnosed by MRI and forms a pro‐tumor immune microenvironment with high expression of PD‐L1, M2 polarization of macrophages and activation of CAFs, which may be a good target for combined immunotherapy. Abstract Background and Aims Immunotherapy has become the standard‐of‐care treatment for hepatocellular carcinoma (HCC), but its ...
Hiroki Murai, Takahiro Kodama, Kazuki Maesaka, Shoichiro Tange, Daisuke Motooka, Yutaka Suzuki, Yasuyuki Shigematsu, Kentaro Inamura, Yoshihiro Mise, Akio Saiura, Yoshihiro Ono, Yu Takahashi, Yota Kawasaki, Satoshi Iino, Shogo Kobayashi, Masashi Idogawa, Takashi Tokino, Tomomi Hashidate‐Yoshida, Hideo Shindou, Masanori Miyazaki, Yasuharu Imai, Satoshi Tanaka, Eiji Mita, Kazuyoshi Ohkawa, Hayato Hikita, Ryotaro Sakamori, Tomohide Tatsumi, Hidetoshi Eguchi, Eiichi Morii, Tetsuo Takehara   +29 more
wiley   +1 more source

Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells [PDF]

, 2018
Sorafenib is the unique accepted molecular targeted drug for the treatment of patients in advanced stage of hepatocellular carcinoma. The current study evaluated cell signaling regulation of endoplasmic reticulum (ER) stress, c-Jun-N-terminal kinase (JNK)
Contreras Bernal, Laura, Cruz Díaz, Jesús de la, Gallego, Paloma, González, Raúl, Navarro Villarán, Elena, Ordóñez, Raquel, Rodríguez Arribas, M., Rodríguez Hernández, María A., Rosa, Ángel J. de la   +8 more
core   +1 more source